THIS SITE IS INTENDED FOR UK AND IRELAND HEALTH PROFESSIONALS ONLY
CREATED BY LEO PHARMA

Tolerability

A pooled analysis of three randomised controlled trials in 1,104 patients demonstrated a positive benefit–risk profile for Enstilar®:1

  • Enstilar® was generally well tolerated in adult patients with plaque psoriasis over a 4-week treatment course
  • No clinically relevant changes were observed in albumin-corrected serum calcium and spot urinary calcium: creatinine ratio during Enstilar® treatment for 4 weeks
  • The authors concluded that Enstilar® provides superior efficacy compared with calcipotriol betamethasone ointment and its individual active ingredients, while maintaining a favourable tolerability profile

The risk of hypercalcaemia is low when the maximum daily dose (15g) of calcipotriol is not exceeded2

References
  1. Menter A et al. Poster presented at the 16th Annual Las Vegas Dermatology Seminar, Las Vegas, USA 5–7 November 2015.
  2. Enstilar® SPC, UK www.medicines.org.uk / IE www.medicines.ie. Last Accessed: August 2018.

UK/IE MAT-04297 V3
Date of preparation: September 2018